The DEPOT Study (Dry Eye Prescription Options for Therapy)

Inclusion Criteria: * Patients 18 years and older * Patients willing to take an electronic survey about their tolerability of either study medication. * Patients with a recent exacerbation of dry eye characterized by ocular surface discomfort. Exclusion Criteria: * Active, systemic or local disease condition other than DES that causes clinically significant ocular surface irritation that could interfere with the evaluation and treatment of dry eye. * Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months prior to the enrollment visit: * Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgery procedure) * Clinically significant ocular trauma. * Active ocular Herpes simplex or Herpes zoster (eye or eyelid) infection. * Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) * Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye) * Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis * Eyelid abnormalities that significantly affect lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) * Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy) * Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to the distribution of the survey * Participation in this trial in the same patient's fellow eye. * Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.